Evidence map›Paper›PMID 27832160›Full record

ArticlePloS one2016

Proteomic Signatures of Thymomas.

Linan Wang, Owen E Branson, Konstantin Shilo, Charles L Hitchcock, Michael A Freitas

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Deciphering the biology of thymic epithelial tumors.Mediastinum (Hong Kong, China) · 2019
    Article
  7. The thymoma tale.The Indian journal of medical research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Linan WangDepartment of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Owen E BransonDepartment of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Konstantin ShiloDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Charles L HitchcockDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Michael A FreitasDepartment of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
The Ohio State University Wexner Medical Center · USThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on the histological features and outcome, the current WHO classification separates thymomas into A, AB, B1, B2 and B3 subtypes. It is hypothesized that the type A thymomas are derived from the thymic medulla while the type B thymomas are derived from the cortex. Due to occasional histological overlap between the tumor subtypes creating difficulties in their separation, the aim of this study was to provide their proteomic characterization and identify potential immunohistochemical markers aiding in tissue diagnosis. Pair-wise comparison of neoplastic and normal thymus by liquid chromatography tandem mass spectrometry (LC-MS/MS) of formalin fixed paraffin embedded tissue revealed 61 proteins differentially expressed in thymomas compared to normal tissue. Hierarchical clustering showed distinct segregation of subtypes AB, B1 and B2 from that of A and B3. Most notably, desmoyokin, a protein that is encoded by the AHNAK gene, was associated with type A thymomas and medulla of normal thymus, by LC-MS/MS and immunohistochemistry. In this global proteomic characterization of the thymoma, several proteins unique to different thymic compartments and thymoma subtypes were identified. Among differentially expressed proteins, desmoyokin is a marker specific for thymic medulla and is potentially promising immunohistochemical marker in separation of type A and B3 thymomas.

Indexed as

AdultAgedBiomarkers, TumorCluster AnalysisFemaleHumansImmunohistochemistryMaleMembrane ProteinsMiddle AgedNeoplasm ProteinsProteomeProteomicsTandem Mass SpectrometryThymomaThymus GlandAHNAK protein, humanBiomarkers, TumorMembrane ProteinsNeoplasm ProteinsProteome

Identifiers

PMID27832160
PMCPMC5104371
OpenAlexW2552558317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.